Fab’entech is a French biotech created in 2009 and specialised in the development and production of polyclonal antibodies intended for the treatment of emerging infectious diseases and biodefense solutions.
Lifestyles, the globalisation of exchanges, the relationship of humans to nature raise fears of multiplying pandemics in the coming years.
Fab’entech offers a modular technological platform which allows the rapid development of effective treatments to deal with the emergence of new infectious diseases or biological threats.
The production of polyclonal antibodies by Fab’entech is based on a safe and proven technology, initially developed by Sanofi Pasteur and enhanced for more than 10 years by the Research & Development teams at Fab’entech.
Fab’entech thus combines the know-how and experience of a large pharmaceutical company with the agility of a biotech.
Fab’entech can count on the skills and energy of an experienced and mobilised team to develop adaptable treatment solutions for the health and safety of people, now and in the future.
CEO and Chairman of the management board
Head of industrial operations
Cécile HERBRETEAU DELALE
Head of Research & Development
Qualified Person, Head of Quality and Pharmaceutical Affairs
Bertrand LEPINE : Founder and family group shareholder
Frédéric HAMMEL : Elaia
Marielle MAILHES : BPI Investment, Definvest fund
Sandra DUBOS : Kreaxi
Guillaume HEMMERLE : Sigma Management
Albert SAPORTA : Censor
Fab’entech is supported by a strong and structuring network of partners. To develop its technology, Fab’entech can count on a network of local, national and international partners who support it in its development.